Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany;
J Immunol. 2014 May 15;192(10):4636-47. doi: 10.4049/jimmunol.1302887. Epub 2014 Apr 16.
De novo regeneration of immunity is a major problem after allogeneic hematopoietic stem cell transplantation (HCT). HCT modeling in severely compromised immune-deficient animals transplanted with human stem cells is currently limited because of incomplete maturation of lymphocytes and scarce adaptive responses. Dendritic cells (DC) are pivotal for the organization of lymph nodes and activation of naive T and B cells. Human DC function after HCT could be augmented with adoptively transferred donor-derived DC. In this study, we demonstrate that adoptive transfer of long-lived human DC coexpressing high levels of human IFN-α, human GM-CSF, and a clinically relevant Ag (CMV pp65 protein) promoted human lymphatic remodeling in immune-deficient NOD.Rag1(-/-).IL-2rγ(-/-) mice transplanted with human CD34(+) cells. After immunization, draining lymph nodes became replenished with terminally differentiated human follicular Th cells, plasma B cells, and memory helper and cytotoxic T cells. Human Igs against pp65 were detectable in plasma, demonstrating IgG class-switch recombination. Human T cells recovered from mice showed functional reactivity against pp65. Adoptive immunotherapy with engineered DC provides a novel strategy for de novo immune reconstitution after human HCT and a practical and effective tool for studying human lymphatic regeneration in vivo in immune deficient xenograft hosts.
异基因造血干细胞移植(HCT)后,新生免疫是一个主要问题。由于淋巴细胞成熟不完全和适应性反应稀少,目前在严重免疫缺陷的动物中移植人类干细胞进行 HCT 建模受到限制。树突状细胞(DC)是淋巴结组织和初始 T 和 B 细胞激活的关键。通过过继转移供体来源的 DC,可以增强 HCT 后人类 DC 的功能。在这项研究中,我们证明了共表达高水平人 IFN-α、人 GM-CSF 和临床相关抗原(CMV pp65 蛋白)的长寿命人 DC 的过继转移促进了免疫缺陷 NOD.Rag1(-/-).IL-2rγ(-/-)小鼠中移植人 CD34(+)细胞后的人淋巴重构。免疫后,引流淋巴结中出现终末分化的人滤泡性 Th 细胞、浆细胞和记忆辅助性和细胞毒性 T 细胞。可在血浆中检测到针对 pp65 的人 Ig,表明 IgG 类别转换重组。从小鼠中回收的人 T 细胞对 pp65 表现出功能性反应。工程化 DC 的过继免疫疗法为人类 HCT 后新生免疫重建提供了一种新策略,也是研究免疫缺陷异种移植宿主体内人类淋巴再生的实用有效工具。